ENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases
Exploration of Neuroscience · 27.05.2025 · 4
DOI: 10.37349/en.2025.100691 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Neuroscience, online erschienen am 27.05.2025. Verfasst von Isadora Cunha Ribeiro und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ectonucleoside triphosphate diphosphohydrolases (ENTPDases), members of the cluster of differentiation 39 (CD39) family, are key regulators of purinergic signaling through the hydrolysis of tri and diphosphate nucleotides. These enzymes are expressed on the cell surface, extracellular environment, or within intracellular organelles such as the Golgi apparatus. ENTPDases play critical roles in modulating immune responses, inflammation, and neuroinflammation by controlling extracellular nucleotide availability in mammals. Moreover, they contribute to adenosine-mediated signaling in cooperation with 5’-nucleotidases (CD73). Pathogenic microorganisms also express ENTPDases, manipulating host purinergic signaling, suppressing adenosine triphosphate (ATP)-driven inflammation, and promoting immune evasion via increased adenosine production. Pathogenic parasites also express ENTPDases, manipulating host purinergic signaling, suppressing ATP-driven inflammation, and promoting immune evasion via increased adenosine production. Given their involvement in infection and inflammatory diseases, ENTPDases have emerged as promising pharmacological targets. This review comprehensively analyzes the ENTPDases from mammals and pathogenic parasites, emphasizing their role in purinergic signaling and their potential as therapeutic targets. While ENTPDase inhibitors hold promise for modulating inflammation and infection, their clinical translation faces challenges, including selectivity, off-target effects, and systemic alterations in purinergic homeostasis. Addressing these concerns through targeted drug delivery, allosteric modulation, and improved inhibitor specificity is crucial for therapeutic advancements.
Zitieren
APA
Ribeiro, I. C., Andrade, A. L. D., Rodrigues, V. D. A., Lima, M. S. L., & Fietto, J. L. R. (2025). ENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases. Exploration of Neuroscience, 4. https://doi.org/10.37349/en.2025.100691
Vancouver
Ribeiro IC, Andrade ALD, Rodrigues VDA, Lima MSL, Fietto JLR. ENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases. Exploration of Neuroscience. 2025;4. doi:10.37349/en.2025.100691
BibTeX
@article{Ribeiro2025,
author = {Ribeiro, Isadora Cunha and Andrade, Amanda Laviola de and Rodrigues, Vitória de Almeida and Lima, Markson Suarez Lacôrte and Fietto, Juliana Lopes Rangel},
title = {ENTPDase inhibitors: therapeutic potential in infectious, inflammatory, and neuroinflammatory diseases},
journal = {Exploration of Neuroscience},
year = {2025},
volume = {4},
doi = {10.37349/en.2025.100691}
}
EUVIMED